Poly(N-acryloyl glycinamide) polymers are soluble in hot aqueous media that gel rapidly on cooling. This gelatin-like behavior was previously compared with drug delivery requirements. Slow releases were demonstrated in vitro using different model molecules and macromolecules and in vivo using methylene blue. Risperidone is a weak basic drug sparingly soluble in water frequently used to treat patients suffering of schizophrenia. A standard risperidone-poly(N-acryloyl glycinamide) hydrogel formulation was selected from which the drug was allowed to release comparatively in buffered and non-buffered isotonic media at 37 °C under pseudo sink conditions. Linear release was observed in pH = 7.4 phosphate buffer whereas in buffer-free 0.15 M NaCl, the release was initially faster than in the buffer but became rapidly slower as the pH increased from 6.8 to 8.2. These features were related to the ionization-dependent solubility of risperidone. In order to minimize the ionization and thus the solubility of the drug inside the hydrogel despite outside buffering at 7.4, Mg(OH2), a sparingly soluble mineral base, was added to the standard formulation. This addition resulted in a c.a. threefold increase of the zero-order release duration. The method should be applicable to other sparingly soluble weakly basic drugs.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Haas HC, Schuler NW. Thermally reversible homopolymer gel systems. J Polym Sci. 1964;2:1095–6.
Haas HC, Moreau RD, Schuler NW. Synthetic thermally reversible gel systems. II J Polym Sci Polym Phys Ed. 1967;5:915–27.
Haas HC, Chiklis CK, Moreau RD. Synthetic thermally reversible gel systems. III J Polym Sci Part A-1 Polym Chem. 1970;8:1131–45.
Boustta M, Colombo P-E, Vert M. Combination of poly(N-acryloyl glycinamide) with at least one active principle. PCT Int. Appl. (2013), WO 2013128373, A1 20130906.
Boustta M, Colombo P-E, Lenglet S, Poujol S, Vert M. Versatile UCST-based thermoresponsive hydrogels for loco-regional sustained drug delivery. J Control Release. 2014;174:1–6.
Bale S, Khurana A, Reddy AS, Singh M, Godugu C. Overview of therapeutic applications of microparticulate drug delivery systems. Crit. Rev. Ther. Drug Carrier Syst. 2016;33:309–61.
Bagratashvili VN, Bogorodskii SE, Egorov AM, Krotova LI, Popov VK, Sevast'yanov VI. Supercritical fluid fabrication of components for a sustained-release injectable risperidone dose form. Russian J Phys Chem B. 2016;10:1123–30.
Acharya G, Shin CS, Vedantham K, McDermott M, Rish T, Hansen K, Fu Y, Park K. A study of drug release from homogeneous PLGA microstructures. J Control Release. 2010;146(2):201–6.
Rabin C, Liang Y, Ehrlichman RS, Budhian A, Metzger KL, Winey KI, Majewski-Tiedeken C, Siegel SJ. In vitro and in vivo demonstration of risperidone implants in mice. Schizophr Res. 2008;98:66–78.
Amann LC, Gandal MJ, Lin R, Liang Y, Siegel SJ. In vitro–in vivo correlations of scalable PLGA-risperidone implants for the treatment of schizophrenia. Pharm Res. 2010;27:1730–7.
Taktak F, Bütün V. Novel zwitterionic ABA-type triblock copolymer for pH- and salt-controlled release of risperidone. Int J Polym Mater Polym Biomater. 2016;65:151–61.
Saha S, Sarkar P, Sarkar M, Giri B. Electroconductive smart polyacrylamide-polypyrrole (PAC-PPY) hydrogel: a device for controlled release of risperidone. RSC Adv. 2015;5:27665–73.
MHRA, Risperidone 0.5mg, 1mg, 2mg, 3mg, 4mg and 6mg Film-Coated Tablets, PL 29412/0002–7 report. http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con123334.pdf.
Hu Z, Liu Y, Yuan W, Wu F, Su J, Jin T. Effect of bases with different solubility on the release behavior of risperidone loaded PLGA microspheres. Coll Surf B Biointerfaces. 2011;86:206–11.
Olesen OV, Licht RW, Thomsen E, Bruun T, Viftrup JE, Linnet K. Serum concentrations and side effects in psychiatric patients during risperidone therapy. Ther Drug Monit. 1998;20:380–4.
Authors are indebted to CNRS, University Montpellier and CNRS for financial supports.
Conflict of interest
The authors declare that they have no conflict of interest.
About this article
Cite this article
Boustta, M., Vert, M. A method to slow down the ionization-dependent release of risperidone loaded in a thermoresponsive poly(N-acryloyl glycinamide) hydrogel. Drug Deliv. and Transl. Res. 7, 460–464 (2017). https://doi.org/10.1007/s13346-017-0376-5
- Poly(N-acryloyl glycinamide)
- Sustained drug delivery
- Gel-sol transition
- Thermoresponsive hydrogel
- Magnesium hydroxide
- Weak base